Clinical Trials Logo

Early-Stage Breast Carcinoma clinical trials

View clinical trials related to Early-Stage Breast Carcinoma.

Filter by:

NCT ID: NCT06387173 Recruiting - Clinical trials for Early Stage Breast Carcinoma

Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer

Start date: January 4, 2024
Phase:
Study type: Observational

This study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer.

NCT ID: NCT06113016 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Prevention of Frailty With Fisetin and Exercise (PROFFi) in Breast Cancer Survivors

PROFFi
Start date: April 17, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that cause inflammation and damage nearby healthy cells. Giving fisetin may eliminate senescent cells in patients with breast cancer undergoing physical activity.

NCT ID: NCT05945290 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

Start date: July 7, 2022
Phase:
Study type: Observational

This study evaluates pre-analytical factors affecting circulating tumor deoxyribonucleic acid (ctDNA) analysis in breast cancer that not spread beyond the breast and or lymph nodes (early and locally advanced). ctDNA refers to freely circulating tumor DNA fragments found in the blood plasma. Pre-analytical factors such as blood collection tubes, delays in separation of plasma, centrifugation speeds, storage conditions, shipping and DNA extraction methods can all affect ctDNA measurements. Inappropriate processing can cause breaking down of the membrane (lysis) of peripheral blood cells that release background wild-type DNA and may also cause degradation of circulating tumor-specific DNA fragments. Both mechanisms will dilute levels of ctDNA in plasma and make it more difficult to detect. Evaluating the pre-analytical factors of the collection of blood and left over tissue samples for the research of cancer may help researchers to evaluate the impact of the blood collection/processing and long-term storage from patients with locally advanced breast cancer.

NCT ID: NCT05417867 Recruiting - Clinical trials for Early Stage Breast Carcinoma

Association Between Changes in the Gut Microbiome and Chemotherapy-Induced Nausea in Stage I-III Breast Cancer

Start date: April 14, 2021
Phase:
Study type: Observational

This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for stage I-III breast cancer. Patients undergoing chemotherapy may experience nausea as a result of their treatment. Known risk factors for CIN do not explain the differences in CIN occurrence between patients, but changes in the functions of the gut microbiome may be related to the occurrence of CIN. This study collects stool samples from breast cancer patients before and after chemotherapy to evaluate how changes in the microbiome may be associated with CIN.

NCT ID: NCT05368428 Recruiting - Clinical trials for Chemotherapy-Induced Peripheral Neuropathy

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

Start date: October 19, 2022
Phase: N/A
Study type: Interventional

This phase II trial examines transcutaneous electrical nerve stimulation (TENS) in patients with stage I-III breast cancer with chemotherapy induced peripheral neuropathy. TENS is a procedure in which mild electric currents are applied to some areas of the skin to potentially improve neuropathy. This trial may help determine if TENS is feasible and effective for the treatment of peripheral neuropathy symptoms while on chemotherapy.

NCT ID: NCT04560439 Withdrawn - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

This trial studies how well a diabetes prevention program (METFIT) works in reducing insulin resistance in stage I-III breast cancer survivors. METFIT program, a diet and lifestyle intervention, utilizes intermittent fasting to reduce insulin resistance in insulin resistant breast cancer survivors. Intermittent fasting has been shown to have benefits for patients undergoing cancer therapy by improving symptoms such as fatigue in breast cancer patients. Intermittent fasting has also shown potential for decreasing the risk of breast cancer coming back (recurrence). This trial is being done to determine if METFIT program can be successfully and effectively implemented to reduce insulin resistant in breast cancer survivors.

NCT ID: NCT04294225 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

Start date: April 28, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer. Drugs, such as anastrozole and letrozole, may stop the growth of tumor cells by decreasing the amount of estrogen made by the body. Giving anastrozole and letrozole after surgery may prevent breast cancer from coming back (recurrence).

NCT ID: NCT04290897 Recruiting - Clinical trials for Anatomic Stage II Breast Cancer AJCC v8

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

Start date: September 29, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well oxaloacetate works in reducing cognitive complaints in stage 0-IIIA breast cancer survivors. Oxaloacetate is a natural substance found in the body and is available as a nutritional supplement. Giving oxaloacetate may reduce inflammation in the brain that could be contributing to cognitive complaints seen after cancer treatments.

NCT ID: NCT04081389 Completed - Clinical trials for Anatomic Stage II Breast Cancer AJCC v8

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Start date: December 6, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer. Chemokine modulation therapy, including celecoxib, recombinant interferon alfa-2b, and rintatolimod, may stimulate the immune system and stop tumor cells from growing. Drugs used in standard chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemokine modulation therapy together with standard chemotherapy may work better than giving either therapy alone in treating patients with triple negative breast cancer.

NCT ID: NCT03077841 Active, not recruiting - Clinical trials for Invasive Breast Carcinoma

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Start date: March 6, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II trial studies how well hypofractionated partial breast irradiation works in treating patients with early stage breast cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Treating only the part of the breast where the cancer started may lead to fewer side effects than standard treatment.